TALKING WITH YOUR DOCTOR
If you visited the “Home” page of this website, you learned that huge differences exist between gene testing and personalized cytometric profiling. The two methods are NOT equivalent. For very good reasons, we believe that cytometric profiling is far superior in identifying effective, personalized patient treatments.
Many physicians seem not to be aware of the limitations of genomic testing despite many editorials on the subject that have appeared respected medical publications. We also often find a serious lack of knowledge on the part of most physicians with respect to newer generation approaches to personalized cytometric cancer profiling.
Much progress has been made in cancer management in general over the past 20 years and personalized cytometric cancer profiling is no execption. But many doctors have not kept pace with newer personalized cytometric cancer profiling approaches. For that reasion your doctor might not be ready to accept that cytometric profiling can be helpful beyond what he or she already knows about choosing drugs. It is likely he or she has knowledge of older methods that were used by other laboratories. Virtually all of those other labs are now out of business.
Most testing methods of just a few years ago are no longer used. The newer and vastly improved methods in use today, especially those used by the Weisenthal Cancer Group, have undergone rigorous scrutiny in more than 100 different studies performed by independent researchers. These studies, published in respected medical journals, all demonstrate high test accuracy.
We would like for you and your physician to understand exactly the level of proof that exists, showing that the use of personalized cytometric cancer profiling can be highly effective in designing successful personalized patient treatments.
Just as importantly, we would like your physician to understand how to use the information provided by your cytometric profiling studies to the best advantage once it is obtained for you.
Larry Weisenthal, M.D., Ph.D. is a medical doctor who is board certified in internal medicine and medical oncology. He was a Clinical Associate at the National Cancer Institute. He is respected as a cancer researcher and as a widely published author and lecturer at international medical meetings and symposia. He also holds a Ph.D. in pharmacology. His knowledge of chemotherapy drugs and how to use them in context with cytometric cancer profiling test results is unsurpassed.
Dr. Weisenthal is pleased to accept a telephone call from your doctor. He can answer your doctor's questions and provide information that will help your doctor to decide if personalized cytometric cancer profiling is right for you.
Dr. Weisenthal also provides collegial consultation to your physician after your tests are completed, to interpret your test results and discuss a therapy plan that offers you the best chance for success.
Dr. Weisenthal's consultation hours for physicians are 11:00 AM until 5:00 PM Pacific Time.
The choice of whether or not to have Dr. Weisenthal perform your personalized cytometric profiling studies is yours alone. Our role is to provide you with any information you or your physician might wish to have in order to make a fully informed choice.
Welcome to the Patients Section of this website. This section is dedicated to cancer patients and others interested in obtaining the maximum benefit from available cancer treatments.
Cancer is not a one-size-fits-all illness. Each patient is unique. That is why a cancer drug that helps one patient often fails to benefit a different patient - even though both patients have the same type of cancer.
Thousands of interrelated biological processes within the cancer cell affect the way each patient responds to treatment. The Weisenthal Cancer Group uses an approach called personalized cytometric profiling to assess the net effect of the widest range of cellular processes as they occur in real time. In the laboratory, your own living cancer cells are exposed to a broad range of potentially beneficial anti-cancer agents. These include new, genetic and molecularly-targeted chemotherapy drugs, immunologic therapies, and anti-angiogenesis agents.
For virtually all cancer types, dozens of different chemotherapy drugs and drug combinations are approved by the FDA. However, for the most part, these are administered blindly. They are prescribed because they worked for some large or small percentage of patients in a past clinical trial. Often, the patient receives one ineffective treatment after another as the doctors work their way down a list of possibilities. While this is occurring, exposure to ineffective drugs induces tumor cell resistance to all forms of chemotherapy (this is called clinically-acquired multi-drug resistance). Meanwhile, the patient becomes weaker and weaker from harmful drug side effects and valuable time is wasted.
Dr. Weisenthal was a pioneer in recognizing the dangers involved in treating patients on the basis of trial and error. For years, he has been a strong voice in demanding reform of a fatally-flawed system. Predictably, his progressive views and outspoken approach did not make him a favorite among pharmaceutical companies or among physicians whose careers revolve around entering patients onto paid clinical trials whose purpose is to identify “one-size-fits-all” cancer therapies. However, Dr. Weisenthal’s persistence has paid-off - at least to a degree. Today, more and more thoughtful physicians are coming to understand that candidate drug regimens must be tested for potential effectiveness FOR EACH PATIENT in the laboratory rather than simply picking drugs blindly from an “approved” list and hoping for the best.
As the number of available treatments increases so does the need to determine which treatment offers you - as an individual - the best possible chance for benefit. In this, Dr. Weisenthal is your most committed advocate and your strongest ally.